Liraglutide 3.0 (Saxenda) in bariatric patients: a retrospective real-world clinical evaluation of effectiveness

Authors

  • Editor Five University of Nottingham
  • Amelia Simenacz (1) Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Medicine, UK
  • Rebekah Wilmington (2) East Midlands Bariatric Metabolic Institute, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK
  • Carol Green (2) East Midlands Bariatric Metabolic Institute, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK
  • Arash Ardavani (2) East Midlands Bariatric Metabolic Institute, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK
  • Iskandar Idris School of Medicine, University of Medicine, Derby, UK

DOI:

https://doi.org/10.15277/bjd.2022.350

Keywords:

Tier 3 service, Tier 4 service, liraglutide, prediabetes, glycaemic control, obesity management

Abstract

Background: Glucagon-like peptide-1 analogues such as liraglutide 3.0 mg (Saxenda) have yielded significant weight loss in clinical trials when combined with lifestyle interventions. Despite the recent approval of liraglutide 3.0 mg, its success among patients attending specialist bariatric units remains uncertain.

Objective: This study investigated the effectiveness of liraglutide 3.0 mg on weight, body mass index (BMI), treatment tolerability and its effects on glycated haemoglobin (HbA1c).

Methods: Clinical data were retrospectively obtained from medical records within Tier 3-4 bariatric weight management clinics. Wilcoxon signed rank tests were employed to establish the statistical significance (p<0.05) of changes in weight and HbA1c.

Results: 33 patients were identified (72.7% female with mean baseline age, weight and BMI of 44.8 years, 156.6 kg and 55.0 kg/m2, respectively). Eighteen patients had completed 26 weeks of treatment. Of the 18 patients, the discontinuation rate due to side effects was 15.2%, indicating substantial treatment tolerance. After 26 weeks of treatment, BMI (±standard deviation) was significantly reduced by 7.9±6.3% (p<0.05) and 72.2% of patients achieved at least 5% weight loss. Additionally, a significant decrease in median HbA1c (4.5±4.5 mmol/mol) was observed (p<0.05), concurrent with increased remission from prediabetes.

Conclusion: This retrospective study revealed that liraglutide 3.0 mg, together with lifestyle management, reduced weight and improved glycaemic control. These results support liraglutide’s application in certain high-risk populations, including patients waiting for bariatric surgical intervention.

References

Parliament UK. Obesity Statistics UK Parliament Library: House of Commons 2021 [cited 2021 22nd October].

Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications. Diabetes Metab Obes 2020;13: 3611-6. https://doi.org:10.2147/DMSO.S275898

Tino S, Mayanja BN, Mubiru MC, et al. Prevalence and factors associated with overweight and obesity among patients with type 2 diabetes mellitus in Uganda; a descriptive retrospective study. Brit Med J Open 2020; 10(11):e039258. https://doi.org/10.1136/bmjopen-2020-039258

Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Blair SN, Church TS. Effects of clinically significant weight loss with exercise training on insulin resistance and cardiometabolic adaptations. Int J Obes 2016; 24(4):812-9. https://doi.org:10.1002/oby.21404

Institute MG. Overcoming obesity: an initial economic analysis [Discussion article]. 2014 [cited 2021 22nd October]. Available from: https://www.mckinsey.com/~/media/mckinsey/business%20functions/economic%20studies%20temp/our%20insights/how%20the%20world%20could%20better%20%EF%AC%81ght%20obesity/mgi_overcoming_obesity_full_report.ashx

Hazlehurst JM, Logue J, Parretti HM, et al. Developing integrated clinical pathways for the management of clinically severe adult obesity: a critique of NHS England policy. Current Obesity Reports 2020;9(4):530- 43. https://doi.org:10.1007/S13679-020-00416-8

NICE. Liraglutide for managing overweight and obesity, technology appraisal guidance [TA664] 2020 [cited 2021 21st October]. Available from: www.nice.org.uk/guidance/ta664.

Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews 2007;87(4):1409-39. https://doi:10.1152/physrev.00034.2006

Bloemendaal LV, Kulve JS, Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014;221(1):1-16. https://doi.10.1530/JOE-13-0414

England PH. Standard Evaluation Framework for Weight Management Interventions 2018 [updated February 2018; cited 2021 21st November]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/685545/SEF_weight_management_interventions.pdf.

NHS Commissioning Board Clinical Reference Group for Severe and Complex Obesity. Clinical commissioning policy: complex and specialised obesity surgery 2013 [cited 2021 12th December]. Available from: https://www.england.nhs.uk/wp-content/uploads/2016/05/appndx-6-policy-sev-comp-obesity-pdf.pdf.

SPSS. IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0 Armonk, NY: IBM Corp.

Alkharaji M, Anyanwagu U, Donnelly R, Idris I. Tier 3 specialist weight management service and pre-bariatric multicomponent weight management programmes for adults with obesity living in the UK: a systematic review. Endocrinol Diabetes Metabol 2019;2:e00042. https://doi.org/10.1002/edm2.42

Le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 2017; 389(10077):1399-409. https://doi.org.10.1016/S0140-6736(17)30069-7

Suliman M, Buckley A, Tikriti A, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab 2019;21(6):1498-501. https://doi.org/10.1111/dom.13672

Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes random- ized clinical trial. JAMA 2015;314(7):687-99. https://doi.org/10.1001/jama.2015.9676

Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE Sleep Apnea randomized clinical trial. Int J Obesity 2016; 40(8):1310-9. https://doi.org/10.1038/ijo.2016.52

Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obesity 2013; 37(11):1443-51. https://doi.org/10.1038/ijo.2013.120

Ferrari F, Fierabracci P, Salvetti G, et al. Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center. J Endocrinol Investig 2020;43:1779-85. https://doi.org/10.1007/s40618-020-01334-1

Gorgojo-Martínez JJ, Basagoiti-Carreño B, Sanz-Velasco A, Serrano- Moreno C, Almodóvar-Ruiz F. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR study. Int J Clin Pract 2019;73(11). https://doi.org/10.1111/ijcp.13399

Downloads

Published

2022-10-18

Issue

Section

Short Communication

Most read articles by the same author(s)